Providing Medication Assisted Treatment for Opioid Use Disorder in Family Medicine Clinics in Vermont

Similar documents
Tips for Successfully Managing Your Type 2 Diabetes

Addiction Recovery Support: Connecting Primary Care Providers and Community Resources

Barriers to recovery for Buprenorphine Patients in Bangor, Maine

Osteoporosis Education: An Insight into Risk Factors & Prevention

Influenza Awareness in Berlin and Montpelier, VT

Lyme Disease: Prevention, Recognition & Treatment

Skill-Based Cooking Class with the Health Care Share

Vitamin D Screening and Supplementation

Management Options for Opioid Dependence:

Vermont Hub and Spoke Model Treatment Need Questionnaire

Attitudes Toward Influenza Vaccination

Fluoride Varnish in the Medical Home

Breaking the Bank: Cost of Cigarettes in Vermont

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Identifying Depression in the Elderly

Report to The Vermont Legislature. Substance Abuse Treatment Services Objectives and Performance Measures Progress: Second Annual Report

Vermont Food Insecurity: Implementing screening tools and interventional assistance at Thomas Chittenden Health Center

Chronic Pain Management: Local Resources and Education

Home Blood Pressure Monitoring Pamphlet

Calcium Supplementation

Opioid Abuse Treatment in Pregnancy

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Promoting Awareness of the Opioid Epidemic in Rural Vermont

Use of Opioids for Pain Management: Educating Patients and Providers on Upcoming Changes to Vermont State Law

Marijuana and the Teenage Brain: Public Health Impact

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity

Optimizing Inhaler Technique

Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Waitsfield, VT

Expanding Access to Dental Care for Patients on Suboxone

The Shingrix Vaccine: Information for Patients About Current Recommendations & the National Shortage

Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS)

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC

Opiate Addiction - The Painkiller Addiction Epidemic, Heroin Addiction And The Way Out By Taite Adams

Strategies to Manage The Opioid Crisis

Addiction Burden and Resources for Patients in Connecticut

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

Chronic Pain Management with High Dose Opioid Medication

Community Perception of Electronic Cigarettes and Their Role as Smoking Cessation Aids

Building Confidence in the Prescribing and Monitoring of Pre-exposure Prophylaxis (PrEP) in Vermont

What would it take to get to zero overdose deaths in California? Kelly Pfeifer, MD May 5, 2017

Assessing Access to Smoking Cessation Resources in Rural Populations

Screening, Identification, Counseling, and Treatment of Opioid Use Disorder

The Care Alliance for Opioid Dependence

Prescription Drug Abuse Task Force Rx Report Card

Provider Resources for Smoking Cessation Counselling

Treatment Approaches for Drug Addiction

Patient Education: Assessing the Barriers to Utilize & Create Effective Educational Resources for Type 2 Diabetes Mellitus (T2DM)

8/16/2018. California s MAT Expansion Hub and Spoke System: Provider and Consumer Perspectives. Agenda. No Wrong Door

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.

Addressing the Opioid Crisis Policy Recommendations

California Hub and Spoke System Evaluation

The Facts - Your Choice: STD Risk Information for the Adolescent Patient

Evaluation of a cancer risk assessment questionnaire to guide cancer screening decisionmaking in primary care

The Importance of Psychological Treatment and Behavioral Support

Status of Opioid Treatment Efforts

Buprenorphine Order Set and Rapid Access Referral. Copyright 2017, CAMH

Child Welfare and MOMS: Building Partnerships to Improve Care

STARTING SUBOXONE IN PRIMARY CARE

Brief History of Methadone Maintenance Treatment

Fighting Today s Opioid Epidemic

Preventing Falls in the Elderly

Diabetes and Your Eyes: The Importance of Annual Eye Exams

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Creating an Effective Education Pamphlet on Sun Protection and Skin Cancer Prevention

Prescription Opioids

Chronic Pain: Decreasing Dependence on Opioids

Management of Opioid Use Disorder in Primary Care

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

Alcoholism Self Assessments, Thomas Chittenden Health Center

Dietary Supplement Education in a Primary Care Setting

Educating High School Students on the Negative Health Effects of Vaping

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Awareness and Prevention of Heroin Use in Springfield VT and a Drug Recovery Resource Map of Southern VT

Identification of Barriers to Organ Donation: A Primary Care Interventional Approach

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP

The Opioid Crisis: What Can Physicians Do About It?

Opioid Use and Other Trends

Substance use and misuse

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

Understanding Medication in Addiction Treatment for Drug Court Participants

THE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT

OUD & MAR: Caring for Our Communities

OPIOIDS IN AMERICA. A complex crisis. A comprehensive response.

Fluoride supplementation: recommendations in the primary care office

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

OPIOID WORKGROUP LEADERSHIP TEAM

NJ SBIRT Project QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Opioid Withdrawal, Opioid Substitution, and HIV Infection

Barriers To Recovery For Bangor's Buprenorphine Patients

Transcription:

University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Providing Medication Assisted Treatment for Opioid Use Disorder in Family Medicine Clinics in Vermont Kelley W. Collier University of Vermont Follow this and additional works at: https://scholarworks.uvm.edu/fmclerk Part of the Medical Education Commons, and the Primary Care Commons Recommended Citation Collier, Kelley W., "Providing Medication Assisted Treatment for Opioid Use Disorder in Family Medicine Clinics in Vermont" (2016). Family Medicine Block Clerkship, Student Projects. 162. https://scholarworks.uvm.edu/fmclerk/162 This Book is brought to you for free and open access by the College of Medicine at ScholarWorks @ UVM. It has been accepted for inclusion in Family Medicine Block Clerkship, Student Projects by an authorized administrator of ScholarWorks @ UVM. For more information, please contact donna.omalley@uvm.edu.

Providing Medication Assisted Treatment (MAT) for Opioid Use Disorder in Family Medicine Clinics in Vermont Kelley Collier UVM College of Medicine, Class of 2018 Rotation 2, May - June 2016 South Burlington, Vermont Project Mentor: Dr. Whitney Calkins 1

Opioid Use Disorder According to the Vermont Department of Health: Opioid use disorder is a major problem in Vermont. Medication assisted treatment was originally developed because detoxification followed by abstinence-oriented treatment had been shown to be unsuccessful in preventing relapse to opiate use. Methadone and Buprenorphine are medications that decrease cravings for opioids. The number of individuals receiving MAT increased by more than 40% in the state of Vermont between 1/1/2013 and 7/30/2014. The number of physicians who are prescribing buprenorphine is only beginning to increase. Many family medicine practitioners affiliated with the University of Vermont started prescribing MAT in March 2016 and many are currently in the waiver process. In an effort to increase the number of MAT providers at various spokes locations in Vermont, many family medicine physicians have recently completed MAT training, or are currently in the process of being trained. By recognizing some of the challenges of prescribing MAT in family medicine clinics and by identifying the concerns of family medicine practitioners regarding becoming MAT providers, family medicine physicians can become more effective at this new role and learn from each other. 2

Public Health Cost of Opioid Use Disorder http://www.cdc.gov/vitalsigns/methadoneoverdoses/index.html 3a

Public Health Cost of Opioid Use Disorder Medication assisted treatment outcomes include: abstention from or reduced use of illicit opiates; reduction in non-opioid illicit drug use (e.g. cocaine); decreased criminal behavior; and decreased risk behavior linked to HIV and hepatitis C. According to the Vermont Department of Health: For every dollar invested in prevention efforts there is a $10-$18 savings in societal cost (health care costs, lost productivity, etc.) Four in five new heroin users started by misusing prescription painkillers. http://www.cdc.gov/vitalsigns/heroin/index.html 94% of respondents in a 2014 survey of people in treatment for opioid addiction said they chose to use heroin because prescription opioids were far more expensive and harder to obtain 3b

Community Perspective Interview with Dr. Thomas Peterson, Professor and Chair, Department of Family Medicine at the University of Vermont, family medicine physician at Colchester Family Practice It s hard to get your head around the idea of harm reduction versus curing patients. The more we [family medicine physicians who are providing MAT] can have common knowledge, the better. A peer support group would be helpful. Interview with Dr. Kathy Mariani, Assistant Professor, Department of Family Medicine at the University of Vermont, family medicine physician at South Burlington Family Practice The key is to have as many MAT providers at one site for support. Interview with Dr. Clara Keegan, Assistant Professor, Department of Family Medicine at the University of Vermont, family medicine physician at South Burlington Family Practice There are a lot of details to keep track of. I don t want to feel like a detective but we also have to stick to rules. We have great resources for ongoing training with the OBOT collaborative. It has been wonderful to learn from each other. 4

Intervention and Methodology Intervention: In an effort to better understand barriers to providing medication assisted treatment to patients with opioid use disorder in family medicine clinics in Vermont, family medicine physicians were asked to identify current challenges to prescribing MAT or concerns about becoming MAT prescribers. Once these challenges and concerns are identified, they will be presented to family medicine physicians. Methodology: Attended MAT training 5/26/16 Developed two surveys, which were reviewed by three physicians at South Burlington Family Practice prior to being dispersed. Asked Lise Vance for permission to have surveys dispersed at Hinesburg, Colchester, Milton, and South Burlington family practice clinics (6/6/16) Asked family medicine physicians (including family medicine residents) to complete the survey (N=26) most-aligned with their current practice: Currently prescribing MAT (n = 9) Not currently prescribing MAT (n = 17) Presented findings to Dr. Whitney Calkins, Site Preceptor at South Burlington Family Practice 6/16/16 5

Survey Results Family Medicine physicians who are currently MAT providers What has been challenging about providing MAT for your patient(s)? Coordinating visits with the MAT team staff Getting patients through the system Hub Day One and then back to clinics Patients not showing up for appointments Would like to provide more services to patients Scheduling What support, if any, is missing from your clinical site to make providing MAT for patients easier? Expectations for ongoing mental health counseling Consistent MAT team support Random pill counts General Themes Most current MAT providers did not know how many other physicians at their clinical site were MAT providers or how many total patients were being prescribed MAT by their clinic. Each family physician, who is currently prescribing MAT and completed the survey, is providing MAT for 1 to 20 patients, with most providing MAT for 1 or 2 patients. Most family physicians currently prescribing MAT responded that the number of their patients that currently need MAT is twice the number of patients currently on MAT. Do you wish you had additional training to be able to successfully provide MAT to a patient? No Yes, more training on inductions OBOT is a great resource Yes, training on co-occurring substance use disorders and for acute pain management 6a

Survey Results Continued Family Medicine Physicians not currently prescribing MAT What concerns, if any, do you have about becoming an MAT provider? Too many other clinical responsibilities How to fit these visits into work day schedule How to make this an organized process Importance of maintaining longitudinal relationships with MAT patients Can create an antagonistic relationship with patient Having support in case prescriber is away The nurse case manager aspect is important Would need more support on-site if providing for more than 30 patients 6b

Evaluation of Effectiveness & Limitations This project achieved its goal of providing family medicine physicians with the opportunity to state their concerns over prescribing medication assisted treatment to individuals with opioid use disorder, as well as identifying barriers to effectively prescribing MAT in a family medicine clinic. Prior to dispersing the surveys, they were evaluated by three different family medicine physicians at the South Burlington clinic; changes were made to the surveys in response to feedback regarding the effectiveness of the survey questions. The information gathered from the surveys was then presented to the site preceptor at the South Burlington clinic and efficacy of survey questions was again evaluated. In response to completing the survey, several physicians stated that it is still very early in the MAT prescribing process for many of them and felt that the survey may be more useful if administered 6 months from now. It would be helpful to administer a followup survey in 6 months, when more family medicine physicians have completed the waiver process and are actively prescribing MAT to patients. Additionally, it would be appropriate to have a pilot peer support group meeting in 6 months to address some of the concerns identified in the surveys. In the future, it would be beneficial to have the surveys reviewed and evaluated by more physicians prior to administering them. Limitations It took quite a bit of time and effort to learn about the implementation and intricacies of prescribing MAT in family medicine clinics. It was important to get feedback from family medicine physicians at multiple sites in order to gain different perspectives on prescribing MAT. It would have been beneficial to have a longer period of time to continue this project in order to develop a pilot peer support group for family medicine physicians who are currently prescribing MAT or are interested in becoming MAT providers. Given that family physicians have very busy clinic schedules, the surveys were only 1 page in-length to encourage completion. This limited the number of questions that were able to be asked. 7

Future Directions Incorporating MAT into one s clinical practice can be daunting; the process involves training, maintaining longitudinal relationships with patients, developing expectations with patients who are being prescribed MAT, and more. As identified through the administered surveys, most FM physicians who are current MAT providers do not know how many other physicians in their clinic are also providing MAT. It could be helpful to develop an effective and easy way for family medicine providers to communicate about the challenges that they have experienced while trying to implement MAT and ways in which they have overcome those challenges. Future projects: o Developing an educational resource for family medicine providers on the MAT induction process. o Surveying family medicine physicians on challenging patient scenarios in the context of providing MAT and how to approach these scenarios. Future interventions: o Holding a peer support meeting once a month with interested physicians who are currently prescribing MAT or are interested in becoming prescribers. At this meeting FM physicians could share challenging patient experiences and develop solutions together. o Further training for interested family medicine physicians on the induction process. Most patients are induced at the Hub and there is currently a waitlist to be induced at the Hub. o Implementation of an MAT trained nurse manager at each clinical site to improve continuity of care and serve as an MAT site expert. 8

References The Effectiveness of Vermont s System of Opioid Addiction Treatment. Vermont Department of Health. http://legislature.vermont.gov/assets/legislative-reports/opioid-system-effectiveness-1.14.15.pdf. Accessed on 6/3/16. Opioid Misuse, Abuse & Dependence in Vermont Data Brief, July 2015. Vermont Department of Health. http://healthvermont.gov/adap/treatment/opioids/documents/data_brief_opioid_misuse_abuse_dependence_ 201507.pdf. Accessed on 6/3/16. Treating Opioid Addiction. Vermont Department of Health. June 2014. Accessed on 6/7/16. Opioid Addiction 2016 Facts & Figures. American Society of Addiction Medicine. http://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf. Accessed on 6/7/16. Injury Prevention & Control: Opioid Overdose. Centers for Disease Control and Prevention. http://www.cdc.gov/drugoverdose/data/overdose.html. Accessed on 6/9/16. Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. The New England Journal of Medicine. January 2016. http://www.nejm.org/doi/full/10.1056/nejmra1508490. Accessed on 6/3/16. Prescription Painkiller Overdoses. Center for Disease Control and Prevention. July 2012. http://www.cdc.gov/vitalsigns/methadoneoverdoses/index.html. Accessed on 6/7/16. 9

Consent Form Thank you for agreeing to be interviewed. This project is a requirement for the Family Medicine clerkship. It will be stored on the Dana Library ScholarWorks website. Your name will be attached to your interview and you may be cited directly or indirectly in subsequent unpublished or published work. The interviewer affirms that he/she has explained the nature and purpose of this project. The interviewee affirms that he/she has consented to this interview. Yes / No If not consenting as above: please add the interviewee names here for the department of Family Medicine information only. Name: 10